Abstract | BACKGROUND: METHODS:
Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing oxaliplatin/5-FU vs. oxaliplatin/ capecitabine were retrospectively analyzed for KRAS mutations. Mutation data were correlated to response data (Overall response rate, ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: 201 patients were analysed for KRAS mutation (61.2% males; mean age 64.2 ± 8.6 years). KRAS mutations were identified in 36.3% of tumors (28.8% in codon 12, 7.4% in codon 13). The ORR in codon 13 patients compared to codon 12 and wild type patients was significantly lower (p = 0.008). There was a tendency for a better overall survival in KRAS wild type patients compared to mutants (p = 0.085). PFS in all patients was not different in the three KRAS genetic groups (p = 0.72). However, we found a marked difference in PFS between patients with codon 12 and 13 mutant tumors treated with infusional 5-FU versus capecitabine based regimens. CONCLUSIONS: TRIAL REGISTRATION NUMBER: 2002-04-017.
|
Authors | Anke Reinacher-Schick, Karsten Schulmann, Dominik P Modest, Nina Bruns, Ulrich Graeven, Malgorzata Jaworska, Richard Greil, Rainer Porschen, Dirk Arnold, Wolff Schmiegel, Andrea Tannapfel |
Journal | BMC cancer
(BMC Cancer)
Vol. 12
Pg. 349
(Aug 09 2012)
ISSN: 1471-2407 [Electronic] England |
PMID | 22876876
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Codon
- KRAS protein, human
- Organoplatinum Compounds
- Proto-Oncogene Proteins
- Oxaliplatin
- Proto-Oncogene Proteins p21(ras)
- ras Proteins
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Codon
- Colorectal Neoplasms
(drug therapy, genetics, mortality, pathology)
- Female
- Humans
- Male
- Middle Aged
- Mutation
- Mutation Rate
- Neoplasm Staging
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Proto-Oncogene Proteins
(genetics)
- Proto-Oncogene Proteins p21(ras)
- Treatment Outcome
- ras Proteins
(genetics)
|